| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA995: Relugolix for treating hormone-sensitive prostate cancer |
|
Medicine details |
|
| Medicine name | Relugolix (Orgovyx®) |
| Formulation | 120 mg film-coated tablets |
| Reference number | 3502 |
| Indication | For the treatment of adult patients with advanced hormone-sensitive prostate cancer |
| Company | Accord-UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/07/2024 |
| NICE guidance | TA995: Relugolix for treating hormone-sensitive prostate cancer |